SETD2 and pancreatic neoplasm: Herein, we highlight that tumor‐intrinsic SETD2 deficiency reshapes the immunosuppressive TME via neutrophils in pancreatic tumorigenesis, potentially providing a therapeutic strategy for pancreatic cancer patients with SETD2 deficiency.